When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. PARP inhibitor - Wikipedia

   en.wikipedia.org/wiki/PARP_inhibitor

   Side effects of PARP inhibitor treatment for cancer may include neutropenia, and a risk of anaemia. [25] People who take this medication also commonly report fatigue. [ 25 ] The toxicity profile of PARP inhibitors when treating cancer has not been found to be more serious than chemotherapy agents, however, further research is needed to ...

3. Rucaparib - Wikipedia

   en.wikipedia.org/wiki/Rucaparib

   Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).

4. Niraparib/abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

   Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).

5. Talazoparib - Wikipedia

   en.wikipedia.org/wiki/Talazoparib

   Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. [6] It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. [9]

6. Olaparib - Wikipedia

   en.wikipedia.org/wiki/Olaparib

   In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...

7. Niraparib - Wikipedia

   en.wikipedia.org/wiki/Niraparib

   [3] [4] It is a PARP inhibitor. The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping ...